Cepeprubart Biosimilar - Research Grade

Human

SELPLG

>1mg/ml

IgG2 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

Q14242

Blue ice

ICH5433 is a research-grade biosimilar of cepeprubart, an unconjugated non-therapeutic analog of the originator antibody supplied for research use only. It is built to reproduce the binding architecture of the originator, which is directed against human SELPLG (P-selectin glycoprotein ligand-1, PSGL-1 / CD162; UniProt Q14242). The molecule is a human IgG2, kappa immunoglobulin and is provided as a full-length antibody without conjugation or reporter modification. As a biosimilar reagent it carries no therapeutic claim and is not a clinical drug; it is intended to give investigators a consistent, well-characterized tool for interrogating the PSGL-1 axis in vitro. Ichor supplies this format at research grade with low endotoxin (typically less than 1 EU/mg), and material is available in bulk milligram-to-gram quantities suitable for assay development, larger screening campaigns, and standardization across experiments. It is well suited to comparability work, epitope and binding studies, and as a defined reference analog of the originator for functional characterization. Ichor should confirm lot-specific isotype, endotoxin, and formulation details before publication or distribution. SELPLG encodes P-selectin glycoprotein ligand-1 (PSGL-1, CD162), a homodimeric mucin-type cell-surface glycoprotein expressed on essentially all leukocytes. Its extended, heavily O-glycosylated extracellular domain presents an N-terminal region bearing tyrosine sulfation and a sialyl-Lewis-x motif that together confer high-affinity binding to P-selectin, and lower-affinity binding to E- and L-selectin. Through these interactions PSGL-1 mediates the initial tethering and rolling of leukocytes on activated endothelium and platelets, a rate-limiting early step in the inflammatory cascade and in leukocyte recruitment to sites of injury. PSGL-1 also contributes to leukocyte aggregation, signaling, and, in T cells, to immune regulation and exhaustion. Its central role in adhesion makes it a target of interest in inflammatory, thrombotic, and immuno-oncology research contexts.

PSGL-1, Selectin P ligand, P-selectin glycoprotein ligand 1

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Cepeprubart biosimilar available in gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities to support bulk and high-throughput preclinical experiments.

Q: Is this research-grade Cepeprubart biosimilar suitable for in vivo studies?

A: Yes, it is supplied in a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Cepeprubart biosimilar target?

A: It is an unconjugated, non-therapeutic research analog of Cepeprubart that binds SELPLG; for research use only.